Skip to main content
OpenTrials
Completed

NCT Number: NCT06556706

Impact of Urolithin A (Mitopure) on Mitochondrial Quality in Muscle of Frail Older Adults

The study is a single-center, randomized, placebo-control double-blind study in frail older adults over 65yrs. to investigate the impact of Mitopure (Urolithin A) supplementation on muscle mitochondrial quality in frail older adults after 8-weeks of supplementation

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

McGill University Health Center

Montreal, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Frail (as defined by the Fried frailty criteria)nonsmoking participants in the age group of 65 to 85 years old, both male and female.
  • A body mass index between 18 to 35 kg/m2.
  • Not on any medications/living with medical conditions that would compromise the study outcome or the safety of the research participant.
  • Able to participate and willing to give written informed consent and to comply with the study restrictions.
  • Willing to be assigned randomly either to the UA or the control group.

Exclusion criteria

Participants must not have:

  • Participated in a clinical trial within 90 days of screening or more than 4 times in the previous year.
  • A history (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol).
  • A history or presence of allergy to 5-aminolevulinic acid or porphyrins.
  • A history or presence of allergy to lidocaine.
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
  • Unwillingness or inability to refrain from consuming alcohol within 48 hours before each visit until the end of said visit.
  • Unwillingness or inability to refrain from consuming 8 or more units of xanthine containing beverages and foods per day during the entire study.
  • Unwillingness to not consume other mitochondrial supplements during the course of the study (such as CoQ10, reseveratrol, NR, NMN etc.) and pomegranate juice
  • unwillingness to not change diet or physical activity levels during the course of the study
  • Unwillingness or inability to undergo a muscle biopsy.
  • Underlying chronic disease, which in the opinion of the investigator, would interfere with study participation or the validity of the measurements.
  • Unintentional weight loss ≤5% of regular body weight during the last 6 months.
  • Medication requirements that may interfere with the interpretation of the results.
  • Loss or donation of blood over 500mL three months prior (male subjects) or four months prior (female subjects) to participating in the study.
  • Smoked (tobacco and/or marijuana mixed with tobacco (THC)) within 6 months prior to the start of the study;
  • Abused drugs, medicine or alcohol within up to 30 days prior to the start of the study (Alcohol: more than 10 drinks a week, with more than 2 drinks a day most days; Drugs: THC, cocaine, opiates, amphetamines/methamphetamines, benzodiazepines, barbiturates, Buprenorphine, Creatin, Methadone metabolite, oxycodone, phencyclidine);
  • A positive COVID-19 test taken 1 week to 24h before study start date.

Treatment and study plan

Mitopure (Urolithin A)

Dietary Supplement

UA is produced by the gut microbiome following the digestion of dietary precursors (polyphenols such as ellagitannins and punicalagins) present in fruits and nuts such as pomegranate, nuts and berries.

In mouse models of aging and muscle dystrophy, UA was shown to induce mitophagy and mitochondrial function in the skeletal muscle. This was associated with improved muscle strength and endurance (Nat. Med, 2016; Sci Tran Med, 2021). In humans, UA was shown to be safe and bioavailable in multiple clinical studies (Nat. Met, 2019; Cell Rep Med, 2022; JAMA Network Open, 2022).

Placebo

Dietary Supplement

Placebo containing excipients other than Urolithin A (Mitopure)

Primary outcomes

  1. Change in mitochondrial area between placebo and active treated groups assessed via Electron Microscopy

    Time frame: 8-weeks

  2. Change in mitochondrial cristae density between placebo and active treated groups assessed via Electron Microscopy

    Time frame: 8-weeks

Secondary outcomes

  1. change between groups on the following: maximal mitochondrial O2 consumption assessed via via respirometry on permeabilized myofibers

    Time frame: 8-weeks

  2. change between groups in mitochondrial calcium retention capacity measured by mitochondrial permeability transition pore (mPTP) sensitivity to calcium

    Time frame: 8-weeks

  3. mitochondrial DNA (mtDNA) over nuclear DNA ratio (mtDNA/nDNA) via qPCR

    Time frame: 8-weeks

  4. Changes in body composition via Dual X-ray Absorptiometry (DXA) scan of total and appendicular lean mass

    Time frame: 8-weeks

  5. Changes in composition via Peripheral quantitative computed tomography (pQCT) of muscle tissue

    Time frame: 8-weeks

  6. Changes in the timed up and go test (time needed to stand from an armchair, walk a distance of 3 meters, turn around and sit back down in the chair)

    Time frame: 8-weeks

  7. Changes in grip strength measured by a hand dynamometer

    Time frame: 8-weeks

  8. Changes in Berg balance test: Participant will be asked to maintain a given position or perform a task

    Time frame: 8-weeks

  9. Changes in distance walked during the six-minute walk test

    Time frame: 8-weeks

  10. Changes in the 30-second stand test: Participant will stand as many times as s/he can from a seated position for 30-seconds.

    Time frame: 8-weeks

  11. Changes in Four-square step test: To assess balance, participant will step over small sticks placed in an X on the floor

    Time frame: 8-weeks

  12. Changes in Unipedal stance test (UPST): First a ball will be kicked to determine dominant leg, then participant will be asked to stand on one leg (barefoot) with eyes open and again with eyes closed

    Time frame: 8-weeks

  13. Recording of adverse events

    Time frame: 8-weeks

  14. Quantification of muscle fiber type (type I/II) via Myosin Heavy Chain immunolabeling

    Time frame: 8-weeks

  15. Analysis of markers of neuromuscular junction integrity (NCAM biomarker staining)

    Time frame: 8-weeks

  16. Changes in knee extension strength measured by a hand dynamometer

    Time frame: 8-weeks

Sponsors and collaborators

Lead sponsor

Amazentis SA

Industry

Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre
  • Université du Québec a Montréal

Registry information

Acronym: MitoEM

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Aug 16, 2024
Registry last updated
May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.